GlassScriptPhysician profile
Efrain Antunez
NPI 1326382169
$1,007.37
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $80.44 · 2021: $279 · 2022: $168 · 2023: $271 · 2024: $47.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $319.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $166.54 | 2021-2023 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $135.00 | 2019-2023 | Xarelto |
| Abbvie INC. | $130.82 | 2023 | Creon |
| Redhill Biopharma INC. | $122.07 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $84.11 | 2020-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $74.39 | 2021-2024 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $58.86 | 2020-2023 | Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $39.36 | 2019-2021 | |
| Pfizer INC. | $37.04 | 2021-2022 | |
| Esperion Therapeutics, INC. | $26.42 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.70 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Efrain Antunez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.